Contact Us | Current Operating Status
Office of News and Public Information
Back | Home
News from NASEM

March 4, 2016

 

Better Evidence, Oversight Needed to Improve Effectiveness and Availability of Biomarker Tests for Molecularly Targeted Therapies, Says New Report

 

WASHINGTON – Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions, says a new report by the National Academies of Sciences, Engineering, and Medicine.  To enhance patient care and clinical outcomes, the report calls for the creation of a “rapid learning system” that would integrate research on these tests and associated treatments with clinical practice.  Appropriate regulatory oversight is also needed to ensure that biomarker tests and targeted therapies are accurate, reliable, and properly validated and implemented.

 

Biomarker tests for molecularly targeted therapies identify molecular variations specific to an individual patient, which can help determine the most effective therapy for a patient’s disease or avoid treatments that could be ineffective or harmful.  Advances in research over the past 15 years have led to hundreds of molecularly targeted agents entering the drug development pipeline; numerous biomarker tests and associated therapies have been approved for clinical use in treating cancer and other diseases.  However, progress has been hampered by regulatory and reimbursement uncertainties, clinical practice challenges, and limitations in data collection and analysis.

 

“The timely development of biomarker tests and associated therapies is critical to realizing the full potential of 'precision medicine,'” said Harold L. Moses, chair of the committee that wrote the report, and Ingram Professor of Cancer Research, professor of medicine, pathology, microbiology, and immunology, and chair of the department of cancer biology at Vanderbilt University.  “Our report lays out a strategy to ensure that patients have access to effective tests and treatments that are based on solid evidence of their ability to improve health outcomes.”

 

The committee identified 10 goals to advance the development and appropriate clinical use of biomarker tests for molecularly targeted therapies.  First and foremost, the U.S. Department of Health and Human Services should immediately facilitate the development of common evidentiary standards that demonstrate the usefulness of biomarker tests for selecting targeted therapies and improving patient outcomes, the report says.  These standards would inform regulatory, insurance coverage, and reimbursement decisions, and they could also strengthen clinical guidelines and standards of care.  To develop and continuously update the standards as new information becomes available, HHS will need ongoing input from a wide variety of stakeholders, including patients, health care providers, test developers, pharmaceutical companies, and relevant government agencies.  HHS should also facilitate collaboration between the U.S. Food and Drug Administration and the Centers for Medicare and Medicaid Services to enable more coordinated, transparent regulatory and reimbursement decisions. 

 

Generating evidence of the overall clinical benefit of any biomarker test should be viewed as a continuous process, the report says.  CMS and private insurance companies should develop payment models to support ongoing data collection on tests and associated therapies.  Currently, data on biomarker tests and patient outcomes are not collected or shared in a way that can inform clinical practice.  Electronic health records and laboratory information systems should facilitate the collection of patient data in real time, including information about tests, treatments, and outcomes.  A national database should be created to capture these data to help health care providers and patients make evidence-based decisions about tests and treatment.  In addition, the processes for developing and updating clinical practice guidelines for the effective use of biomarker tests for molecularly targeted therapies should be improved so that new data are incorporated and a broader base of interdisciplinary expertise is involved, the report says.

 

Some patients may face challenges in obtaining access to biomarker tests and therapies because of economic, ethnic, cultural, or geographic barriers.  The report calls for research on how to provide equitable access to biomarker tests and targeted treatments.  And to empower patients and their health care providers to make informed decisions, the FDA should develop patient- and provider-friendly standardized labels and additional information about tests' performance, evidence, and uses.

 

Oversight and accreditation of laboratories providing biomarker tests for molecularly targeted therapies should also be updated and strengthened, the report says.  Current regulatory oversight of these labs is widely viewed as insufficient for increasingly complex biomarker tests.  And professional organizations and health care institutions should develop and implement standards for obtaining patient specimens to ensure patient safety as well as the accuracy of biomarker test results.

 

The study by the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine was sponsored by the American Society for Radiation Oncology, American Society of Clinical Oncology, Breast Cancer Research Foundation, Centers for Disease Control and Prevention, College of American Pathologists, Gilead Sciences, Janssen Diagnostics, National Cancer Institute, Novartis, Pfizer, Quest Diagnostics, and Susan G. Komen.  The Academies are private, nonprofit institutions that provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, technology, and medicine.  The Academies operate under an 1863 congressional charter to the National Academy of Sciences, signed by President Lincoln.  For more information, visit http://national-academies.org.  A committee roster follows.

 

Social Media: #Biomarkers

Report in Brief

 

Contacts:

Molly Galvin, Senior Media Relations Officer

Emily Raschke, Media Assistant

Office of News and Public Information

202-334-2138; e-mail news@nas.edu

http://national-academies.org/newsroom

Twitter: @theNASEM

RSS feed: http://www.nationalacademies.org/rss/index.html

Flickr: http://www.flickr.com/photos/nationalacademyofsciences/sets

 

Copies of Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine are available at www.nap.edu.  Reporters may obtain a copy from the Office of News and Public Information (contacts listed above).

 

#          #          #

 

THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE

Institute of Medicine

Board on Health Care Services

 

Committee on Policy Issues in the Clinical Development and Use of

Biomarkers for Molecularly Targeted Therapies

 

Harold L. Moses, M.D.* (chair)

Ingram Professor of Cancer Research

Professor of Cancer Biology, Medicine, and Pathology

Chair, Department of Cancer Biology

Director Emeritus, Vanderbilt-Ingram Comprehensive Cancer Center

Vanderbilt University Medical Center

Nashville, Tenn.

 

John M. Carethers, M.D.*

John G. Searle Professor and Chair

Department of Internal Medicine

Professor of Human Genetics

University of Michigan Health System

Ann Arbor

 

Molly Cooke, M.D.*

Professor of Medicine and Director of Education

Global Health Sciences

University of California

San Francisco

 

Garret A. FitzGerald, M.D., F.R.S.*

Professor of Medicine and Pharmacology

McNeil Professor in Translational Medicine and Therapeutics

Chair, Department of Pharmacology

Director, Department of Pharmacology

Institute for Translational Medicine and Therapeutics

Perelman School of Medicine

University of Pennsylvania

Philadelphia

 

Felix Frueh, Ph.D.

Executive Director

Opus Three LLC

Del Mar, Calif.

 

Debra Leonard, M.D., Ph.D.

Professor and Chair of Pathology and Laboratory Medicine

University of Vermont Medical Center

UV College of Medicine

Burlington

 

Gary H. Lyman, M.D., M.P.H.

Co-Director, Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences and Clinical Research Divisions. Fred Hutchinson Cancer Research Center

Professor of Medicine, Public Health, and Pharmacy

University of Washington

Seattle

 

Robert L. Nussbaum, M.D., FACP, FACMG*

Chief Medical Officer

Invitae

San Francisco

 

Rebecca D. Pentz, Ph.D.

Professor of Research Ethics

Winship Cancer Institute

Emory University School of Medicine

Atlanta

 

Jane Perlmutter, Ph.D.,M.B.A.

President and Founder

Gemini Group

Ann Arbor, Mich.

 

Victoria M. Pratt, Ph.D.

Director ,Pharmacogenomics Laboratory

Department of Medical and Molecular Genetics

Indiana University School of Medicine

Indianapolis

 

Yu Shyr, Ph.D.

Harold L. Moses Chair in Cancer Research, Director, Vanderbilt Center for Quantitative Sciences Director, Vanderbilt Technologies for Advanced Genomics, Analysis and Research Design

Professor, Department of Biostatistics, Bioinformatics, Cancer Biology and Health Policy

Vanderbilt University

Nashville

 

Sean Tunis, M.D., M.Sc.

Founder, President, and CEO

Center for Medical Technology Policy

Baltimore

 

Tracey F. Weisberg, M.D.

President

New England Cancer Specialists

Scarborough

 

 

STAFF

 

Laurene Graig, M.A.

Study Director

 

________________

*Member, National Academy of Medicine